425: Alumis and ACELYRIN Amend Merger Agreement, Increasing ACELYRIN Stockholder Ownership

Alumis and ACELYRIN have amended their merger agreement, increasing the ownership stake for ACELYRIN stockholders in the combined company to approximately 48% on a fully diluted basis.

Summary

• Alumis and ACELYRIN have amended their previously announced merger agreement.
• Under the amended terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock.
• This revision increases ACELYRIN stockholders' ownership in the combined company to approximately 48% on a fully diluted basis, while Alumis stockholders will own approximately 52%.
• The boards of both companies, acting on the recommendation of special committees, have unanimously approved the amended agreement.
• Stockholders representing approximately 62% of Alumis voting common stock and approximately 24% of ACELYRIN common stock have entered into voting agreements in support of the transaction.
• The companies expect to close the transaction in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• The combined company is expected to have a pro forma cash position of approximately $737 million as of December 31, 2024, providing runway into 2027.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the improved terms for ACELYRIN stockholders and the expected benefits of the merger, such as a stronger financial position and a diversified pipeline. However, risks associated with the merger and integration temper the overall optimism.

Positives

• ACELYRIN stockholders will receive a greater ownership stake in the combined company.
• The merger is expected to create a leading clinical-stage immunology company with a diversified portfolio.
• The combined company is expected to have sufficient cash runway to advance its pipeline through multiple data readouts and fund operations into 2027.
• Both companies' boards have unanimously approved the amended agreement based on recommendations from special committees.
• Stockholders representing a significant portion of both companies' shares have entered into voting agreements in support of the transaction.

Negatives

• The merger is subject to stockholder approval and customary closing conditions, which could delay or prevent the transaction from closing.
• Integration of the two companies' operations and personnel could present challenges.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.

Risks

• The proposed merger may not be completed in a timely manner or at all.
• Required approvals, including stockholder approvals, may not be received.
• The announcement, pendency, or completion of the merger could negatively impact the companies' ability to attract and retain key personnel and maintain relationships.
• The merger could divert management's attention from ongoing business operations.
• Legal proceedings related to the merger could arise.
• Economic, business, and competitive factors could adversely affect Alumis or ACELYRIN.
• The anticipated benefits and synergies of the merger may not be fully realized.
• Integration of the two companies post-closing may not occur as anticipated.
• There are risks related to the value of Alumis securities to be issued in the merger.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials exist.

Future Outlook

The combined company expects to advance its pipeline through multiple planned key data readouts across several clinical trials and to fund operating expenses and capital expenditure requirements into 2027.

Management Comments

• Martin Babler, President, Chief Executive Officer and Chairman of Alumis, stated that the revised terms enable enhanced value creation opportunities for stockholders and provide financial flexibility to advance the pipeline.
• Bruce Cozadd, Chair of the ACELYRIN Board of Directors, said that the amended agreement reflects conversations with stockholders and builds upon the previously announced agreement.

Industry Context

The merger aims to create a stronger player in the competitive immunology space, combining Alumis' precision approach with ACELYRIN's late-stage assets. This consolidation reflects a broader trend in the biopharmaceutical industry to build larger, more diversified companies with greater financial resources and pipeline depth.

Comparison to Industry Standards

• The revised ownership split, giving ACELYRIN stockholders 48% of the combined company, is within the typical range for mergers of this type, where deal terms are adjusted based on market conditions and stockholder feedback.
• The pro forma cash position of $737 million is substantial and provides a competitive advantage compared to smaller biotech companies that may struggle to fund late-stage clinical trials.
• Similar mergers in the biopharmaceutical industry, such as Pfizer's acquisition of Arena Pharmaceuticals, demonstrate the strategic rationale of acquiring promising pipelines to bolster long-term growth.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN are impacted by the revised ownership structure and the potential for long-term value creation.
• Employees of both companies may experience changes related to integration and restructuring.
• Patients could benefit from the combined company's ability to advance a broader pipeline of therapies.

Next Steps

• Alumis and ACELYRIN will file supplemental proxy materials with the SEC.
• The companies will hold their respective Special Meetings of Stockholders on May 13, 2025.
• The companies will work to satisfy customary closing conditions to complete the transaction in the second quarter of 2025.

Key Dates

Keywords

merger, ACELYRIN, Alumis, stockholders, agreement, common stock, ownership, clinical-stage, immunology, pipeline